{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis', 'or syndrome should be recorded on the AE page/screen of the eCRF. If the abnormality was not', 'a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.', 'If possible, the laboratory abnormality should be recorded as a medical term and not simply as an', 'abnormal laboratory result (eg, record thrombocytopenia rather than decreased platelets).', '10.4.', 'Pregnancy', 'All pregnancies or suspected pregnancies occurring in either a female subject of childbearing', 'potential or partner of childbearing potential of a male subject are immediately reportable events.', '10.4.1.', 'Females of Childbearing Potential - Collection of Pregnancy Information', 'Pregnancies and suspected pregnancies (including elevated \u00df-hCG or positive pregnancy test in a', 'female subject of childbearing potential regardless of disease state) occurring while the subject is', \"on IP, or within 28 days of the subject's last dose of IP, are considered immediately reportable\", 'events. Investigational product is to be discontinued immediately. A female subject with', 'suspected pregnancy may resume IP after a confirmed negative pregnancy test and consultation', 'with the sponsor. The pregnancy, suspected pregnancy, or positive pregnancy test must be', 'reported to Amgen Global Patient Safety, or designee, immediately by email, facsimile, or', 'other appropriate method, using the Pregnancy Notification Form or approved equivalent form', '(refer to Appendix T). The Pregnancy Notification Form must be submitted to Amgen Global', \"Patient Safety within 24 hours of learning of a subject's pregnancy. (Note: Sites are not required\", 'to provide any information on the Pregnancy Notification Form that violates the country or', 'regions local privacy laws).', \"After obtaining the female subject's signed consent for release of pregnancy and infant health\", 'information, the investigator will collect pregnancy and infant health information and complete', 'the pregnancy questionnaire for any female subject who becomes pregnant while taking IP', \"through 28 days of the subject's last dose of IP. This information will be forwarded to Amgen\", 'Global Patient Safety. Generally, infant follow-up will be conducted 12 months after the birth of', 'the child (if applicable).', 'The female subject may be referred to an obstetrician-gynecologist or another appropriate', 'healthcare professional for further evaluation.', 'The Investigator will monitor the progress of the pregnancy of a female subject, and must notify', 'Amgen Global Patient Safety immediately about the outcome of the pregnancy (either normal or', 'abnormal outcome).', 'If the outcome of the pregnancy was abnormal (eg, spontaneous or therapeutic abortion), the', 'Investigator should report the abnormal outcome as an AE. If the abnormal outcome meets any', 'of the serious criteria, it must be reported as an SAE to Amgen Global Patient Safety by', \"facsimile, email or other appropriate method, within 24 hours of the investigator's knowledge of\", 'the event using the paper SAE Report Form.', 'All neonatal deaths that occur within 28 days of birth should be reported, without regard to', 'causality, as SAEs. In addition, any infant death after 28 days that the Investigator suspects is', 'related to the in-utero exposure to the IP should also be reported as an SAE to Amgen Global', 'Confidential and Proprietary', '55', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Patient Safety, by facsimile, email, or other appropriate method, within 24 hours of the', \"investigator's knowledge of the event using the paper SAE Report Form.\", '10.4.2.', 'Male Subject With Partners Who Become Pregnant', 'In the event a male subject fathers a child during treatment, and for an additional 28 days after', 'discontinuing IP, the information will be recorded on the Pregnancy Notification Form (refer to', 'Appendix T). The form must be submitted to Amgen Global Patient Safety with 24 hours of the', \"investigator's/site awareness of the pregnancy (Note: Sites are not required to provide any\", 'information on the Pregnancy Notification Form that violates the country or regions local', 'privacy laws).', 'The investigator will attempt to obtain a signed consent for release of pregnancy and infant', 'health information directly from the pregnant female partner to obtain additional pregnancy', 'information.', \"After obtaining the female partner's signed consent for release of pregnancy and infant health\", 'information the investigator will collect pregnancy outcome and infant health information on the', 'pregnant partner and her baby and complete the pregnancy questionnaires. This information will', 'be forwarded to Amgen Global Patient Safety.', 'Generally, infant follow-up will be conducted up to 12 months after the birth of the child (if', 'applicable).', 'Any termination of the pregnancy will be reported to Amgen Global Patient Safety regardless of', 'fetal status (presence or absence of anomalies) or indication for procedure,', '10.4.3.', 'Collection of Lactation Information', 'Investigator will collect lactation information on any female subject who breastfeeds', 'while taking IP through 28 days post last dose of IP.', 'Information will be recorded on the Lactation Notification Form (refer to Appendix U)', 'and submitted by facsimile or email to Amgen Global Patient Safety within 24 hours of', \"the investigator's knowledge of event.\", 'Study treatment will be discontinued if female subject breastfeeds during the study.', 'With the female subjects signed consent for release of mother and infant health', 'information, the investigator will collect mother and infant health information and', 'complete the lactation questionnaire on any female subject who breastfeeds while taking', 'IP through 28 days after discontinuing IP.', '10.5.', 'Reporting of Serious Adverse Events', 'Any AE that meets any serious criterion requires the completion of the relevant eCRFs and the', 'paper SAE report form. All SAEs must be reported to Amgen Global Patient Safety within 24', \"hours of the Investigator's knowledge of the event by sending the SAE data/information using\", 'the paper SAE report form. This instruction pertains to initial SAE reports as well as any', 'follow-up reports.', 'The Investigator is required to ensure that the data on these forms are accurate and consistent.', 'This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study', 'Confidential and Proprietary', '56', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}